As Pipelines Wither, Pharma and FDA Explore Whether Microarrays are Ready for Primetime

As Pipelines Wither, Pharma and FDA Explore Whether Microarrays are Ready for Primetime
When can the pharmaceutical industry start trusting the technology? When should it make the leap from investigative, experimental technique to industry standard? And should the FDA start using microarray data to make critical decisions about the safety and efficacy of new drugs?


Leave a Reply

Your email address will not be published. Required fields are marked *

Get email updates

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Subscribe!